The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Access the Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Osteoporosis Drugs Market Report Highlights

·        Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

·        Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

·        In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

·        Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

·        The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Order your free sample copy of “Osteoporosis Drugs Market Report 2024 - 2030, published by Grand View Research

Key Osteoporosis Drugs Company Insights

Some key companies in the osteoporosis drugs market include Amgen Inc; Eli Lilly and Company; Merck & Co., Inc.; Novartis AG; GlaxoSmithKline plc; Pfizer Inc.; Radius Health Inc.; UCB S. A.; Teva Pharmaceuticals Industries Ltd. in the market are focusing on the development of osteoporosis drugs to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives.

·        Amgen Inc. develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicine for treating cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders, and nephrology conditions.

·        Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent-protected prescription medicines, generic pharmaceuticals, and biosimilars.

Key Osteoporosis Drugs Companies:

The following are the leading companies in the osteoporosis drugs market. These companies collectively hold the largest market share and dictate industry trends.

·        Amgen Inc.

·        Eli Lilly and Company

·        Merck & Co., Inc.

·        Novartis International AG

·        Pfizer Inc.

·        GlaxoSmithKline plc

·        Radius Health, Inc.

·        UCB S.A.

·        Teva Pharmaceutical Industries Ltd.

·        Roche Holding AG

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  [email protected]